<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163342</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-FLZ-401</org_study_id>
    <nct_id>NCT03163342</nct_id>
  </id_info>
  <brief_title>Immune Response Following Seasonal Influenza Vaccination</brief_title>
  <official_title>Extent and Durability of Immune Response Following Seasonal Influenza Vaccination in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Optimal Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single administration dose study in adult healthy male and female
      subjects. After qualifying for the study, subjects will receive a single intramuscular
      injection of the FDA approved 2016-2017 quadrivalent influenza vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be screened within 28 days prior to enrollment into the study. After qualifying
      for the study subjects will visit the clinical unit on Day l and will have pre-dose blood
      samples taken for humoral (serum) and cellular(peripheral blood mononuclear cells PBMCs)
      immunity testing and nasopharyngeal swabs for assessment of mucosa! immunity, and will then
      be given the vaccine.

      Over the next 6 months, I 0-mL blood samples will be collected on Days 4, 8, 15, 29, 91 and
      181 for HAI testing. Peripheral blood mononuclear cells will be collected on Day 8 to assess
      cellular responses. A nasopharyngeal swab will also be done on Day 29. Screening assessments
      will include clinical laboratory tests (hematology, chemistry, urinalysis (UA), drug and
      alcohol testing), vital signs, 12-lead electrocardiogram and physical examination.

      Adverse events (AEs) will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Actual">June 15, 2018</completion_date>
  <primary_completion_date type="Actual">November 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain</measure>
    <time_frame>Day 29 after vaccine</time_frame>
    <description>To evaluate antibody response against matched influenza strain H1N1 A/California/04/2009 strain as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Response to Divergent Influenza Strains</measure>
    <time_frame>Day 29 after vaccine</time_frame>
    <description>l) antibody responses to divergent influenza strains as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Immune Response</measure>
    <time_frame>Day 8 after vaccine</time_frame>
    <description>To evaluate cellular immune responses to influenza as measured by PBMC ELISpot following administration of seasonal influenza vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal Influenza Antibody Response</measure>
    <time_frame>Day 29 after vaccine</time_frame>
    <description>To evaluate mucosal influenza antibody responses as measured by IgA ELISA following administration of seasonal influenza vaccine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Licensed seasonal influenza vaccine, intramuscular</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed seasonal influenza vaccine</intervention_name>
    <description>20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women 18 to 50 years of age, inclusive

          2. Good general health status, as determined by the Investigator

          3. Adequate venous access for repeated phlebotomies

          4. Screening laboratory results within institutional normal range or Grade 1 elevation if
             the Investigator documents clinical insignificance. Bilirubin may be Grade 2 if
             associated with no1mal alanine aminotransferase (ALT) and aspartate aminotransferase
             (AST) and the Investigator considers the result not to be clinically significant (e.g.
             vigorous exercise or Gilbert's syndrome)

          5. Negative drug and alcohol screen at Screening and pre-dose on Day I

          6. For women of child bearing potential, negative pregnancy test

          7. Willingness to practice a highly effective method of contraception that may include,
             but is not limited to, abstinence, sex only with persons of the same sex,monogamous
             relationship with a postmenopausal partner, monogamous relationship with vasectomized
             partner, vasectomy, surgical sterilization (hysterectomy, or bilateral tubal ligation,
             salpingectomy, or oophorectomy), licensed hormonal methods, intrauterine device (IUD),
             or consistent use of a barrier method (e.g., condom, diaphragm) with spermicide for 28
             days after the Fluzone Intramuscular Quadrivalent vaccine dose.

        Exclusion Criteria:

          1. Pregnant, possibly pregnant, or lactating women

          2. Body mass index&gt; 35.0 kg/m2

          3. Positive results for HIV, hepatitis B vims, or hepatitis C virus at Screening

          4. Asthma or other chronic lung disease that is greater than mild in severity.
             Specifically excluded are participants with any of the following events in the past
             year:

               -  Daily symptoms

               -  Daily use of short acting beta 2 agonists

               -  Use of inhaled steroids or theophylline

               -  Use of pulse systemic steroids

               -  Emergency care or hospitalization related to asthma or other chronic lung disease

               -  Systemic steroids for asthma exacerbation

          5. History of diabetes mellitus (gestational diabetes is allowed if treatment was not
             required postpartum and serum glucose is currently in the normal range)

          6. History of coronary artery disease, arrhythmia, or congestive heart failure

          7. Clinically significant ECG abnormality

          8. Poorly controlled hypertension (systolic blood pressure &gt; 150 mmHg or diastolic blood
             pressure &gt; 95 mmHg) at Screening or pre-dose on Day I

          9. History of anaphylaxis or angioedema

         10. Known allergy to any of the ingredients in the vaccine formulation including egg
             allergy

         11. History of chronic rhinitis, nasal septal defect,cleft palate, nasal polyps, or other
             nasal abnormality that might affect vaccine administration

         12. Previous nasal surgery or nasal cauterization

         13. Any symptoms of upper respiratory infection or temperature&gt; 38Â°C within 3 days before
             Day I

         14. Significant nasal congestion or rhinorrhea as assessed by the investigator.

         15. Known or suspected malignancy, excluding non-melanoma skin cancers and other early
             stage surgically excised malignancies that the Investigator considers to be
             exceedingly unlikely to recur

         16. Immunocompromised individuals, including those who have used corticosteroids
             (including intranasal steroids), alkylating drugs, antimetabolites, radiation,
             immune-modulating biologics, or other immunomodulating therapies within 90 days before
             Day 1 or those who plan use during the study period

         17. Use of statin medication within 30 days before Day I (including atorvastatin,
             fluvastatin,lovastatin, pravastatin, rosuvastatin, simvastatin, pitavastatin)

         18. Receipt of intranasal medications (including over-the-counter medications) within 30
             days before Day 1

         19. Receipt of any IP within 30 days before Day 1

         20. Receipt of any vaccine within 30 days before Day I

         21. Receipt of intranasal vaccine within 90 days before Day I

         22. Receipt of any influenza vaccine within 6 months before Day I

         23. Any change in medication for a chronic medical condition within 30 days before Day I

         24. Past regular use or current use of intranasal illicit drugs or any regular use of
             illicit drugs by any other route.

         25. Use of tobacco products or electronic cigarettes within 30 days before Day l. Any
             other smoking products including marijuana will be excluded.

         26. Any medical, psychiatric, or social condition or any occupational or other
             responsibility that in the judgment of the Investigator would interfere with or serve
             as a contraindication to protocol adherence, assessment of safety (including
             immunogenicity), or a subject's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Bart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimal Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Health Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <results_first_submitted>March 6, 2019</results_first_submitted>
  <results_first_submitted_qc>April 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seasonal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03163342/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03163342/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label</title>
          <description>Licensed seasonal influenza vaccine, intramuscular
Licensed seasonal influenza vaccine: 20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label</title>
          <description>Licensed seasonal influenza vaccine, intramuscular
Licensed seasonal influenza vaccine: 20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" lower_limit="21" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain</title>
        <description>To evaluate antibody response against matched influenza strain H1N1 A/California/04/2009 strain as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine.</description>
        <time_frame>Day 29 after vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FluZone</title>
            <description>Open label</description>
          </group>
        </group_list>
        <measure>
          <title>HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain</title>
          <description>To evaluate antibody response against matched influenza strain H1N1 A/California/04/2009 strain as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine.</description>
          <units>Geometric Mean Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.4" lower_limit="186.7" upper_limit="461.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response to Divergent Influenza Strains</title>
        <description>l) antibody responses to divergent influenza strains as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine</description>
        <time_frame>Day 29 after vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FluZone</title>
            <description>Open label</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Divergent Influenza Strains</title>
          <description>l) antibody responses to divergent influenza strains as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine</description>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane/59/2007 (H1 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="6.9" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Jersey/76 (H1 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="22.5" upper_limit="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Saint-Petersburg/61/2015 (H1 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="21.8" upper_limit="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam/1203/2004XPR8 (H5 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="6.0" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cellular Immune Response</title>
        <description>To evaluate cellular immune responses to influenza as measured by PBMC ELISpot following administration of seasonal influenza vaccine</description>
        <time_frame>Day 8 after vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FluZone</title>
            <description>Open label</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Immune Response</title>
          <description>To evaluate cellular immune responses to influenza as measured by PBMC ELISpot following administration of seasonal influenza vaccine</description>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="14.3" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mucosal Influenza Antibody Response</title>
        <description>To evaluate mucosal influenza antibody responses as measured by IgA ELISA following administration of seasonal influenza vaccine</description>
        <time_frame>Day 29 after vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FluZone</title>
            <description>Open label</description>
          </group>
        </group_list>
        <measure>
          <title>Mucosal Influenza Antibody Response</title>
          <description>To evaluate mucosal influenza antibody responses as measured by IgA ELISA following administration of seasonal influenza vaccine</description>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.2" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 through Day 181</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FluZone</title>
          <description>Open label</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie Holland, Clinical Project Manager</name_or_title>
      <organization>Altimmune</organization>
      <phone>240 ext 40</phone>
      <email>Sholland@altimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

